Cytokinetics Inc (CYTK) Stock Analysis
Verdict: HOLD
Commercial pivot via MYQORZO launch justifies a speculative premium, but massive debt and insider selling demand disciplined entry.
Investment score: 64/100
Analysis as of
Is Cytokinetics Inc stock worth reviewing? AI model thesis
Cytokinetics is transitioning to a commercial-stage biotech with the launch of aficamten. While clinical risks are declining, commercial execution and a heavy debt-to-equity profile are the new primary risks.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 50/100 (weight 15%)
- Technical Momentum: 78/100 (weight 15%)
- Earnings Quality: 45/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 92/100 (weight 10%)
- Risk-Adjusted Return: 70/100 (weight 15%)
Cytokinetics Inc opportunities and risks
What speaks for CYTK
- Global Commercialization of MYQORZO (aficamten)
What speaks against CYTK
- Debt Burden and Financial Overhang
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CYTK | n/a | 86.6x | n/a | 90.3% | -784.0% | -6.0% |
| MDGL | n/a | 9.8x | n/a | 93.1% | -27.3% | -2.5% |
| BMRN | 39.4x | 3.3x | 20.4x | 75.9% | 8.3% | 7.2% |
| ARWR | n/a | 17.0x | n/a | 100.0% | -48.4% | -0.5% |
| PRAX | n/a | 0.0x | n/a | 0.0% | 0.0% | -4.0% |
| KRYS | 38.8x | 21.1x | 44.7x | 92.8% | 53.9% | 2.7% |
| Peer median | n/a | 9.8x | n/a | 92.8% | 0.0% | -0.5% |
Frequently asked questions about Cytokinetics Inc (CYTK)
Is CYTK stock a good investment?
The cached TradeMates AI model rates Cytokinetics Inc as HOLD with an investment score of 64/100. Cytokinetics is transitioning to a commercial-stage biotech with the launch of aficamten. While clinical risks are declining, commercial execution and a heavy debt-to-equity profile are the new primary risks. This is algorithmic model output, not personal investment advice.
Is CYTK stock a buy?
The TradeMates model verdict for CYTK is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.